Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hypersensitivity Reaction

  Free Subscription


Articles published in J Am Acad Dermatol

Retrieve available abstracts of 130 articles:
HTML format



Single Articles


    November 2021
  1. GUO L, Bai H, Botto N, Woodruff CM, et al
    Allergens and Marketing Claims in Commercial Hand Sanitizers: A Cross-Sectional Study.
    J Am Acad Dermatol. 2021 Nov 24. pii: S0190-9622(21)02895.
    PubMed    


  2. ROH YS, Huang AH, Sutaria N, Choi U, et al
    Real-world comorbidities of atopic dermatitis in the U.S. adult ambulatory population.
    J Am Acad Dermatol. 2021 Nov 17. pii: S0190-9622(21)02838.
    PubMed     Abstract available


  3. CHOVATIYA R, Silverberg JI
    DESCRIBE-AD: A Novel Classification Framework for Atopic Dermatitis.
    J Am Acad Dermatol. 2021 Nov 10. pii: S0190-9622(21)02795.
    PubMed     Abstract available


    October 2021
  4. PALLER AS, Mina-Osorio P, Vekeman F, Boklage S, et al
    Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence.
    J Am Acad Dermatol. 2021 Oct 28. pii: S0190-9622(21)02720.
    PubMed     Abstract available


  5. SAEKI H, Ito K, Yokota D, Tsubouchi H, et al
    Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized double-blind vehicle-controlled trial.
    J Am Acad Dermatol. 2021 Oct 25. pii: S0190-9622(21)02682.
    PubMed     Abstract available


  6. GHAFARI G, Liszewski W
    Comparison of the formulation and allergenic potential of "clean" and traditional shampoos.
    J Am Acad Dermatol. 2021 Oct 22. pii: S0190-9622(21)02684.
    PubMed    


  7. KAUPPI S, Jokelainen J, Timonen M, Tasanen K, et al
    Atopic dermatitis and the risk of eating disorders: a population-based cohort study.
    J Am Acad Dermatol. 2021 Oct 21. pii: S0190-9622(21)02674.
    PubMed    


  8. RAKITA U, Kaundinya T, Silverberg JI
    Lack of association between atopic dermatitis severity and worsening during pregnancy: a cross-sectional study.
    J Am Acad Dermatol. 2021 Oct 7. pii: S0190-9622(21)02585.
    PubMed    


  9. WU JJ, Martin A, Liu J, Thatiparthi A, et al
    The risk of COVID-19 infection in patients with atopic dermatitis - a retrospective cohort study.
    J Am Acad Dermatol. 2021 Oct 6. pii: S0190-9622(21)02578.
    PubMed    


    September 2021
  10. SILVERBERG JI, Hou A, Warshaw EM, Maibach HI, et al
    Prevalence and Trend of Allergen Sensitization in Patients with a Diagnosis of Seborrheic Dermatitis After Patch Testing, North American Contact Dermatitis Group Data, 2001-2016.
    J Am Acad Dermatol. 2021 Sep 25. pii: S0190-9622(21)02522.
    PubMed    


  11. MOLOGOUSIS M, Goldminz AM
    References for Common Contact Allergens Present in Prescription Topical Corticosteroids.
    J Am Acad Dermatol. 2021 Sep 24. pii: S0190-9622(21)02490.
    PubMed    


  12. BAJWA H, Baghchechi M, Mujahid M, Kang-Dufour MS, et al
    Mixed evidence on the relationship between socioeconomic position and atopic dermatitis: a systematic review.
    J Am Acad Dermatol. 2021 Sep 18. pii: S0190-9622(21)02493.
    PubMed     Abstract available


  13. MANJUNATH J, Silverberg JI
    Association of obesity in early childhood with atopic dermatitis in late childhood and adolescence.
    J Am Acad Dermatol. 2021 Sep 3. pii: S0190-9622(21)02393.
    PubMed    


    August 2021
  14. IMHOF RL, Weaver AL, St Sauver J, Hand JL, et al
    Association between topical corticosteroid use and fracture risk among pediatric patients with atopic dermatitis.
    J Am Acad Dermatol. 2021 Aug 21. pii: S0190-9622(21)02367.
    PubMed    


  15. BLAUVELT A, Silverberg JI, Lynde CW, Bieber T, et al
    Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.
    J Am Acad Dermatol. 2021 Aug 17. pii: S0190-9622(21)02343.
    PubMed     Abstract available


  16. BERNA R, Margolis DJ, Barbieri JS
    Attrition of topical calcineurin inhibitor use over time in atopic dermatitis.
    J Am Acad Dermatol. 2021 Aug 11. pii: S0190-9622(21)02292.
    PubMed    


  17. LI H, Dai T, Liu C, Liu Q, et al
    Phenotypes of atopic dermatitis and the risk for subsequent asthma: a systematic review and meta-analysis.
    J Am Acad Dermatol. 2021 Aug 9. pii: S0190-9622(21)02273.
    PubMed     Abstract available


  18. CHOI EC, Heng YK, Lim YL
    Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions.
    J Am Acad Dermatol. 2021;85:e109.
    PubMed    


  19. MOLINA GE, Otto TS, Yu Z, Foreman RK, et al
    Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions".
    J Am Acad Dermatol. 2021;85:e111-e112.
    PubMed    


  20. O'BRIEN KF, Bradley SE, Mitchell CM, Cardis MA, et al
    Vulvovaginal manifestations in Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevention and treatment.
    J Am Acad Dermatol. 2021;85:523-528.
    PubMed     Abstract available


  21. SHAH R, Chen ST, Kroshinsky D
    Use of cyclosporine for the treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    J Am Acad Dermatol. 2021;85:512-513.
    PubMed    


  22. KRIDIN K, Cohen AD
    Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis.
    J Am Acad Dermatol. 2021;85:501-503.
    PubMed    


    July 2021
  23. MANJUNATH J, Silverberg JI
    Association of sleep disturbances with geriatric age in atopic dermatitis patients.
    J Am Acad Dermatol. 2021 Jul 29. pii: S0190-9622(21)02191.
    PubMed    


  24. COLLIS RW, Tam I, Snyder A, Plante J, et al
    Evaluating the Inclusiveness of Common Allergens in Expanded Series Patch Tests for Children in the Pediatric Allergic Contact Dermatitis Registry.
    J Am Acad Dermatol. 2021 Jul 24. pii: S0190-9622(21)02176.
    PubMed    


  25. EDIGIN E, Kichloo A, El-Amir Z, Wani F, et al
    National Trends in Hospitalizations of Atopic Dermatitis Adult Patients: A 21-Year Longitudinal United States Population Based Study.
    J Am Acad Dermatol. 2021 Jul 9. pii: S0190-9622(21)02084.
    PubMed    


  26. PARK SK, Kim JS, Seo HM
    Exposure to air pollution and incidence of atopic dermatitis in the general population: A national population-based retrospective cohort study.
    J Am Acad Dermatol. 2021 Jul 6. pii: S0190-9622(21)02066.
    PubMed     Abstract available


  27. MCMAHON DE, Amerson E, Rosenbach M, Lipoff JB, et al
    Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    J Am Acad Dermatol. 2021;85:46-55.
    PubMed     Abstract available


  28. ELSTON DM
    This Month in JAAD: July 2021.
    J Am Acad Dermatol. 2021;85:33.
    PubMed    


  29. DURON D, Blaise S, Cracowski JL, Roustit M, et al
    Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database.
    J Am Acad Dermatol. 2021;85:229-232.
    PubMed    


    June 2021
  30. RICK JW, Alavi A, Hsiao JL, Yosipovitch G, et al
    Atopic Dermatitis and Hidradenitis Suppurativa: An Under-recognized Pair.
    J Am Acad Dermatol. 2021 Jun 29. pii: S0190-9622(21)01995.
    PubMed    


  31. WILLIAMS HC
    New topical treatments for atopic dermatitis - active comparators are needed.
    J Am Acad Dermatol. 2021 Jun 18. pii: S0190-9622(21)01098.
    PubMed    


  32. NARLA S, Silverberg JI, Simpson EL
    Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
    J Am Acad Dermatol. 2021 Jun 11. pii: S0190-9622(21)01119.
    PubMed     Abstract available


  33. NAKAGAWA H, Nemoto O, Igarashi A, Saeki H, et al
    Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
    J Am Acad Dermatol. 2021 Jun 9. pii: S0190-9622(21)01116.
    PubMed     Abstract available


  34. SCHAFFER JV
    Pediatric Game Changers *: Topical calcineurin inhibitors for pediatric periorificial dermatitis.
    J Am Acad Dermatol. 2021;84:1798.
    PubMed    


  35. CHEN CB, Hsu TH, Chung-Yee Hui R, Lu CW, et al
    Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    J Am Acad Dermatol. 2021;84:1782-1791.
    PubMed     Abstract available


  36. KANTOR J
    June 2021: Acute generalized exanthematous pustulosis in Asia.
    J Am Acad Dermatol. 2021;84:1544.
    PubMed    


  37. BOULL CL, Gardeen S, Abdali T, Li E, et al
    Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study.
    J Am Acad Dermatol. 2021;84:1554-1561.
    PubMed     Abstract available


    May 2021
  38. SCHWARTZ BL, Honari G, Chiou AS, Ko J, et al
    Prevalence of Potentially Allergenic Ingredients in Products Labeled for Eczema Care.
    J Am Acad Dermatol. 2021 May 28. pii: S0190-9622(21)01030.
    PubMed    


  39. SHERMAN S, Bitan DT, Leshem YA, Hodak E, et al
    Reply to: Comments on "Hidradenitis Suppurativa and Atopic Dermatitis: A Two-Way Association".
    J Am Acad Dermatol. 2021 May 24. pii: S0190-9622(21)01004.
    PubMed    


  40. PAPP K, Szepietowski JC, Kircik L, Toth D, et al
    Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies.
    J Am Acad Dermatol. 2021 May 3. pii: S0190-9622(21)00931.
    PubMed     Abstract available


  41. JO CE, Finstad A, Georgakopoulos JR, Piguet V, et al
    Facial and neck erythema associated with dupilumab treatment: A systematic review.
    J Am Acad Dermatol. 2021;84:1339-1347.
    PubMed     Abstract available


    April 2021
  42. GAO DX, Kahn JS, Cohen SR, Fiumara K, et al
    Treatment of patients with atopic dermatitis with weekly dupilumab dosing: a single institutional retrospective medical record review and survey.
    J Am Acad Dermatol. 2021 Apr 21. pii: S0190-9622(21)00883.
    PubMed    


  43. HONG MR, Lei D, Yousaf M, Chavda R, et al
    A real-world study of the longitudinal course of skin-pain in adult atopic dermatitis.
    J Am Acad Dermatol. 2021 Apr 16. pii: S0190-9622(21)00820.
    PubMed    


  44. WOHLTMANN W
    JAAD Game Changers: Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study.
    J Am Acad Dermatol. 2021 Apr 11. pii: S0190-9622(21)00757.
    PubMed    


  45. HEYMANN WR
    SkinSerious: Disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis.
    J Am Acad Dermatol. 2021;84:911-912.
    PubMed    


  46. WANG Y, Jorizzo JL
    Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.
    J Am Acad Dermatol. 2021;84:1010-1014.
    PubMed     Abstract available


  47. ATWATER AR, Petty AJ, Liu B, Green CL, et al
    Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016.
    J Am Acad Dermatol. 2021;84:965-976.
    PubMed     Abstract available


  48. SILVERBERG JI, Warshaw EM, Atwater AR, Maibach HI, et al
    Hand dermatitis in adults referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2000 to 2016.
    J Am Acad Dermatol. 2021;84:989-999.
    PubMed     Abstract available


  49. WARSHAW EM, Kullberg SA, DeKoven JG, Maibach HI, et al
    Scalp involvement in patients referred for patch testing: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 1996 to 2016.
    J Am Acad Dermatol. 2021;84:977-988.
    PubMed     Abstract available


  50. MUFTI A, Lytvyn Y, Maliyar K, Sachdeva M, et al
    Drugs associated with development of pityriasis rubra pilaris: A systematic review.
    J Am Acad Dermatol. 2021;84:1071-1081.
    PubMed    


  51. WARSHAW EM, Voller LM, Maibach HI, Zug KA, et al
    Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016.
    J Am Acad Dermatol. 2021;84:953-964.
    PubMed     Abstract available


  52. TAM I, Gole H, Martin KL, Goldminz AM, et al
    Cross-sectional evaluation of the pediatric baseline series in detection of contact sensitization in children.
    J Am Acad Dermatol. 2021;84:1123-1126.
    PubMed    


  53. GEHLHAUSEN JR, Wetter DA, Nelson C, Ramachandran S, et al
    A detailed analysis of the distribution, morphology, and histopathology of complex purpura in hospitalized patients: A case series of 68 patients.
    J Am Acad Dermatol. 2021;84:1188-1196.
    PubMed     Abstract available


    March 2021
  54. MEROLA JF, Bagel J, Almgren P, Ropke M, et al
    Tralokinumab Does Not Impact Vaccine-induced Immune Responses: Results From a 30-week, Randomized, Placebo-controlled Trial in Adults With Moderate-to-severe Atopic Dermatitis.
    J Am Acad Dermatol. 2021 Mar 17. pii: S0190-9622(21)00577.
    PubMed     Abstract available


  55. HUANG AH, Roh YS, Sutaria N, Choi J, et al
    Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States.
    J Am Acad Dermatol. 2021 Mar 6. pii: S0190-9622(21)00507.
    PubMed     Abstract available


  56. BOSMA AL, de Wijs LEM, Hof MH, van Nieuwenhuizen BR, et al
    Reply to "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'".
    J Am Acad Dermatol. 2021 Mar 3. pii: S0190-9622(21)00469.
    PubMed    


  57. CHENG BT, Silverberg JI
    Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study.
    J Am Acad Dermatol. 2021 Mar 2. pii: S0190-9622(21)00465.
    PubMed     Abstract available


  58. SEO HM, Oh SU, Park SK, Kim JS, et al
    Comment on "Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry".
    J Am Acad Dermatol. 2021 Mar 2. pii: S0190-9622(21)00468.
    PubMed    


  59. WARSHAW EM, Kullberg SA, Atwater AR, DeKoven JG, et al
    Currently relevant p-phenylenediamine patch test reactions associated with hair dye and nonscalp anatomic areas: Retrospective cross-sectional analysis of North American Contact Dermatitis Group data, 2001 to 2016.
    J Am Acad Dermatol. 2021;84:e175-e177.
    PubMed    


  60. YAN BY, Wasilewski G, Lacouture ME, Barker CA, et al
    Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis.
    J Am Acad Dermatol. 2021;84:871-875.
    PubMed    


  61. JUNG MJ, Kim JC, Wei ET, Selescu T, et al
    A randomized, vehicle-controlled clinical trial of a synthetic TRPM8 agonist (Cryosim-1) gel for itch.
    J Am Acad Dermatol. 2021;84:869-871.
    PubMed    


  62. THOMPSON LL, Pan CX, Chang MS, Krasnow NA, et al
    Impact of ethnicity on the diagnosis and management of cutaneous toxicities from immune checkpoint inhibitors.
    J Am Acad Dermatol. 2021;84:851-854.
    PubMed    


  63. HAWRO T, Przybylowicz K, Spindler M, Hawro M, et al
    The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study.
    J Am Acad Dermatol. 2021;84:691-700.
    PubMed     Abstract available


  64. GAO X, Tang X, Ai L, Gao Q, et al
    Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.
    J Am Acad Dermatol. 2021;84:644-653.
    PubMed     Abstract available


  65. WANG LL, Noe MH, Micheletti RG
    Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort.
    J Am Acad Dermatol. 2021;84:784-786.
    PubMed    


    February 2021
  66. COTTON C
    JAAD Game Changers: Sleep disturbance in children with moderate/severe atopic dermatitis: A case-control study.
    J Am Acad Dermatol. 2021 Feb 25. pii: S0190-9622(21)00342.
    PubMed    


  67. JO CE, Mufti A, Sachdeva M, Pratt M, et al
    Effect of dupilumab on allergic contact dermatitis and patch testing.
    J Am Acad Dermatol. 2021 Feb 19. pii: S0190-9622(21)00403.
    PubMed    


  68. SIMPSON EL, Forman S, Silverberg JI, Zirwas M, et al
    Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).
    J Am Acad Dermatol. 2021 Feb 15. pii: S0190-9622(21)00353.
    PubMed     Abstract available


  69. GRONBECK C, Feng PW, Feng H
    Differences in dermatologic patient complexity based on practice setting.
    J Am Acad Dermatol. 2021;84:522-524.
    PubMed    


  70. YU J, Chen JK, Mowad CM, Reeder M, et al
    Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review.
    J Am Acad Dermatol. 2021;84:486-494.
    PubMed     Abstract available


  71. TSAI TY, Huang IH, Chao YC, Li H, et al
    Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis.
    J Am Acad Dermatol. 2021;84:390-397.
    PubMed     Abstract available


  72. STOLL JR, Vaidya TS, Mori S, Dusza SW, et al
    Association of interleukin-6 and tumor necrosis factor-alpha with mortality in hospitalized patients with cancer.
    J Am Acad Dermatol. 2021;84:273-282.
    PubMed     Abstract available


    January 2021
  73. MCKENZIE PL, Castelo-Soccio L
    Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis.
    J Am Acad Dermatol. 2021 Jan 20. pii: S0190-9622(21)00195.
    PubMed    


  74. SCHWARTZMAN G, Lei D, Yousaf M, Janmohamed SR, et al
    Validity and reliability of Patient-Reported Outcomes Measurement Information System Global Health scale in adults with atopic dermatitis.
    J Am Acad Dermatol. 2021 Jan 20. pii: S0190-9622(21)00180.
    PubMed     Abstract available


  75. SMIESZEK SP, Przychodzen B, Welsh SE, Brzezynski JL, et al
    Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale based endotypes in atopic dermatitis.
    J Am Acad Dermatol. 2021 Jan 6. pii: S0190-9622(21)00005.
    PubMed    


  76. LEWINSON RT, Meyers DE, Vallerand IA, Suo A, et al
    Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy.
    J Am Acad Dermatol. 2021;84:183-185.
    PubMed    


  77. HALLING AS, Loft N, Silverberg JI, Guttman-Yassky E, et al
    Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    J Am Acad Dermatol. 2021;84:139-147.
    PubMed     Abstract available


  78. MARZANO AV, Genovese G, Tavecchio S, Germiniasi F, et al
    Clinical and immunopathologic features of idiopathic cutaneous immunoglobulin M/G vasculitis versus idiopathic skin-limited immunoglobulin A vasculitis.
    J Am Acad Dermatol. 2021;84:175-178.
    PubMed    


    December 2020
  79. SHERMAN S, Kridin K, Bitan DT, Leshem YA, et al
    Hidradenitis Suppurativa and Atopic Dermatitis: A Two-Way Association.
    J Am Acad Dermatol. 2020 Dec 27. pii: S0190-9622(20)33250.
    PubMed     Abstract available


  80. ALI Z, Andersen AD, Bjerre-Christensen T, Zibert JR, et al
    Agreement between dermatologists' selection of the lesional area and characteristics best representing atopic dermatitis severity: online survey.
    J Am Acad Dermatol. 2020 Dec 22. pii: S0190-9622(20)33236.
    PubMed    


  81. DRAELOS ZD, Ports WC, Vlahos B, Yeoh T, et al
    Skin permeation and penetration of crisaborole when coapplied with emollients.
    J Am Acad Dermatol. 2020;83:1801-1803.
    PubMed    


    November 2020
  82. RAVN NH, Ahmadzay ZF, Christensen TA, Larsen HHP, et al
    Bidirectional Association between Atopic Dermatitis, Conjunctivitis and other Ocular Surface Diseases: A Systemic Review and Meta-Analysis.
    J Am Acad Dermatol. 2020 Nov 27. pii: S0190-9622(20)33077.
    PubMed     Abstract available


  83. NEALE H, Garza-Mayers AC, Tam I, Yu J, et al
    Pediatric Allergic Contact Dermatitis. Part II. Patch Testing Series, Procedure, and Unique Scenarios.
    J Am Acad Dermatol. 2020 Nov 17. pii: S0190-9622(20)32909.
    PubMed     Abstract available


  84. NEALE H, Garza-Mayers AC, Tam I, Yu J, et al
    Pediatric Allergic Contact Dermatitis. Part I. Clinical Features and Common Contact Allergens in Children.
    J Am Acad Dermatol. 2020 Nov 17. pii: S0190-9622(20)32910.
    PubMed     Abstract available


  85. PATHANIA YS, Budania A
    Comment on "Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines".
    J Am Acad Dermatol. 2020;83:e363-e364.
    PubMed    


  86. GABRIELLI S, Le M, Netchiporouk E, Miedzybrodzki B, et al
    Reply to "Comment on: 'Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines'".
    J Am Acad Dermatol. 2020;83:e365-e366.
    PubMed    


  87. LIPNER SR, Wang Y
    Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration.
    J Am Acad Dermatol. 2020;83:1527-1529.
    PubMed    


  88. MUZUMDAR S, Zubkov M, Waldman R, DeWane ME, et al
    Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review.
    J Am Acad Dermatol. 2020;83:1520-1521.
    PubMed    


  89. HOFFMAN KP, Chung C, Parikh S, Kwatra SG, et al
    Immunoglobulin A expression in adult cutaneous leukocytoclastic vasculitis and its effect on hospital outcomes.
    J Am Acad Dermatol. 2020;83:1511-1513.
    PubMed    


  90. GEISLER AN, Phillips GS, Barrios DM, Wu J, et al
    Immune checkpoint inhibitor-related dermatologic adverse events.
    J Am Acad Dermatol. 2020;83:1255-1268.
    PubMed     Abstract available


  91. SIMONSEN AB, Kaae J, Ellebaek E, Svane IM, et al
    Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    J Am Acad Dermatol. 2020;83:1415-1424.
    PubMed     Abstract available


  92. KIM GY, Anderson KR, Davis DMR, Hand JL, et al
    Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature.
    J Am Acad Dermatol. 2020;83:1323-1330.
    PubMed     Abstract available


  93. MOLINA GE, Yu Z, Foreman RK, Reynolds KL, et al
    Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series.
    J Am Acad Dermatol. 2020;83:1475-1477.
    PubMed    


  94. PETTY AJ, Cardones AR, Marano AL
    Analysis of clinical characteristics of drug-induced cutaneous lupus erythematosus in men.
    J Am Acad Dermatol. 2020;83:1455-1457.
    PubMed    


    October 2020
  95. SCHNEEWEISS MC, Kim SC, Wyss R, Schneeweiss S, et al
    Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study.
    J Am Acad Dermatol. 2020 Oct 7. pii: S0190-9622(20)32685.
    PubMed     Abstract available


  96. ELLIS SR, Vierra AT, Millsop JW, Lacouture ME, et al
    Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
    J Am Acad Dermatol. 2020;83:1130-1143.
    PubMed     Abstract available


  97. LOWE AJ, Lee B, Orchard D, King E, et al
    Palm reading and water divining: A cross-sectional study of the accuracy of palmar hyperlinearity and transepidermal water loss to identify individuals with a filaggrin gene null mutation.
    J Am Acad Dermatol. 2020;83:1186-1188.
    PubMed    


  98. CUNNINGHAM L, Menzies S, Moore E, Shudell E, et al
    Mucocutaneous adverse effects of the genital and perianal skin from isotretinoin therapy.
    J Am Acad Dermatol. 2020;83:1174-1175.
    PubMed    


  99. LEE H, Jung SJ, Patel AB, Thompson JM, et al
    Racial characteristics of alopecia areata in the United States.
    J Am Acad Dermatol. 2020;83:1064-1070.
    PubMed     Abstract available


    September 2020
  100. VAN DER KOLK TN, Buters TP, Krouwels L, Boltjes J, et al
    Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.
    J Am Acad Dermatol. 2020 Sep 30. pii: S0190-9622(20)32659.
    PubMed     Abstract available


  101. CHENG J, Jiang L, Morrow NC, Avdic A, et al
    Recognition of Atopic Keratoconjunctivitis During Treatment with Dupilumab for Atopic Dermatitis.
    J Am Acad Dermatol. 2020 Sep 18. pii: S0190-9622(20)32636.
    PubMed    


  102. RUGE IF, Thorsteinsdottir S, Norgaard S, Chawes BL, et al
    Symptom burden of atopic dermatitis in early childhood assessed from daily monitoring of symptoms and topical steroid usage.
    J Am Acad Dermatol. 2020 Sep 17. pii: S0190-9622(20)32626.
    PubMed     Abstract available


  103. ARIENS LF, van der Schaft J, Spekhorst LS, Bakker DS, et al
    Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry.
    J Am Acad Dermatol. 2020 Sep 15. pii: S0190-9622(20)32618.
    PubMed     Abstract available


  104. CHO YT, Yang CW, Chen YC, Chu CY, et al
    Comment on "Viral reactivation in hospitalized DRESS patients: A retrospective study from a tertiary medical center in the United States".
    J Am Acad Dermatol. 2020;83:e209-e210.
    PubMed    


  105. MILANI-NEJAD N, Trinidad J, Kaffenberger BH
    Reply to: "Comment on Viral reactivation in hospitalized DRESS patients: A retrospective study from a tertiary medical center in the United States".
    J Am Acad Dermatol. 2020;83:e211.
    PubMed    


    August 2020
  106. MARTINEZ-LOPEZ A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, et al
    Review of adverse cutaneous reactions of pharmacologic interventions for coronavirus disease 2019 (COVID-19): a guide for the dermatologist.
    J Am Acad Dermatol. 2020 Aug 7. pii: S0190-9622(20)32358.
    PubMed     Abstract available


  107. HEYMANN WR
    Topical tacrolimus and malignancy risk: Should the theory be put to rest?
    J Am Acad Dermatol. 2020;83:367-368.
    PubMed    


  108. SHARMA AN, Mesinkovska NA, Paravar T
    Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review.
    J Am Acad Dermatol. 2020;83:563-578.
    PubMed     Abstract available


  109. HU S, Shangraw S, Newman S
    Assessing practice gaps in the outpatient management of cutaneous small vessel vasculitis.
    J Am Acad Dermatol. 2020;83:657-659.
    PubMed    


  110. BRAY JK, Johnson MC, Masicampo EJ, Feldman SR, et al
    Optimizing presentation of expected treatment outcomes.
    J Am Acad Dermatol. 2020;83:602-604.
    PubMed    


    July 2020
  111. SASIDHARANPILLAI S, Ajithkumar K, Khader A, Reena Mariyath OK, et al
    Drug reaction with eosinophilia and systemic symptoms within 1 week of exposure to the drug.
    J Am Acad Dermatol. 2020;83:e17-e18.
    PubMed    


  112. MILANI-NEJAD N, Trinidad J, Kaffenberger BH
    Viral reactivation in hospitalized patients with drug reaction with eosinophilia and systemic symptoms: A retrospective study from a tertiary medical center in the United States.
    J Am Acad Dermatol. 2020;83:278-279.
    PubMed    


  113. ISOM J, Braswell DS, Siroy A, Auerbach J, et al
    Clinical and histopathologic features differentiating acute generalized exanthematous pustulosis and pustular psoriasis: A retrospective series.
    J Am Acad Dermatol. 2020;83:265-267.
    PubMed    


  114. YANES D, Nguyen E, Imadojemu S, Kroshinsky D, et al
    Cyclosporine for treatment of acute generalized exanthematous pustulosis: A retrospective analysis.
    J Am Acad Dermatol. 2020;83:263-265.
    PubMed    


    June 2020
  115. HEYMANN WR
    The renal reality of adult Henoch-Schonlein purpura.
    J Am Acad Dermatol. 2020;82:1303-1304.
    PubMed    


  116. JACOBSEN AA, Pearson DR
    The age of procalcitonin: potential pitfalls in critically ill patients with SJS/TEN. A comment on "Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients".
    J Am Acad Dermatol. 2020;82:e247.
    PubMed    


  117. KOH HK, Lee HY
    Reply to: "The age of procalcitonin: Potential pitfalls in critically ill patients with SJS/TEN. A comment on 'Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients
    J Am Acad Dermatol. 2020;82:e249.
    PubMed    


  118. SEMINARIO-VIDAL L, Kroshinsky D, Malachowski SJ, Sun J, et al
    Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults.
    J Am Acad Dermatol. 2020;82:1553-1567.
    PubMed     Abstract available


  119. JUSTO ADS, Lemes BM, Nunes B, Antunes KA, et al
    Depth of injury of Hetter's phenol-croton oil chemical peel formula using 2 different emulsifying agents.
    J Am Acad Dermatol. 2020;82:1544-1546.
    PubMed    


  120. SINGH P, Silverberg JI
    Adverse event monitoring in patients on oral systemic medications for inflammatory skin disease.
    J Am Acad Dermatol. 2020;82:1537-1539.
    PubMed    


  121. GABRIELLI S, Le M, Netchiporouk E, Miedzybrodzki B, et al
    Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines.
    J Am Acad Dermatol. 2020;82:1535-1537.
    PubMed    


  122. WANG CY, Zheng RRC, Doerrer ZA, Kurta AO, et al
    Health care regulation, the Food and Drug Administration (FDA), and access to medicine: Our experience with dupilumab for children.
    J Am Acad Dermatol. 2020;82:1568-1569.
    PubMed    


  123. BAUMRIN E, Azzawi S, St John J, Hoang MP, et al
    Prognostic implications of normal or minimal urinary findings on long-term renal impairment in adults with Henoch-Schonlein purpura.
    J Am Acad Dermatol. 2020;82:1393-1399.
    PubMed     Abstract available


    May 2020
  124. MOLINA GE, Yanovsky RL, Wei EX, Chen ST, et al
    Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: A 9-year retrospective review.
    J Am Acad Dermatol. 2020;82:1255-1258.
    PubMed    


  125. LESHEM YA, Chalmers JR, Apfelbacher C, Furue M, et al
    Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.
    J Am Acad Dermatol. 2020;82:1181-1186.
    PubMed     Abstract available


  126. COLLIS RW, Sheinbein DM
    Cocamidopropyl betaine is commonly found in hypoallergenic personal care products for children.
    J Am Acad Dermatol. 2020;82:1245-1247.
    PubMed    


    April 2020
  127. KHOSRAVI H, Zhang S, Anderson AM, Ferris LK, et al
    Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States.
    J Am Acad Dermatol. 2020;82:1023-1024.
    PubMed    


  128. HEBERT AA, Siegfried EC, Durham T, de Leon EN, et al
    Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial.
    J Am Acad Dermatol. 2020;82:887-894.
    PubMed     Abstract available


  129. HASAN ALI O, Bomze D, Ring SS, Berner F, et al
    BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.
    J Am Acad Dermatol. 2020;82:854-861.
    PubMed     Abstract available


    February 2020
  130. KIM EJ, Geskin L, Guitart J, Querfeld C, et al
    Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
    J Am Acad Dermatol. 2020 Feb 20. pii: S0190-9622(20)30057.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: